MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News:
Medincell (Paris:MEDCL):
Christophe Douat, Chief Executive Officer, Dr. Richard Malamut, Chief Medical Officer, and Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will participate at the following conferences in December:
8th Annual Evercore Healthcare Conference (Miami, Dec. 2-4)
Fireside chat on Wednesday, December 3, 2025, at 9:35am ET (3:35pm CET)
Live webcast and replay: https://wsw.com/webcast/evercore52/medcl/2521706
Piper Sandler 37th Annual Healthcare Conference (New-York, Dec. 2-4)
Fireside chat on Thursday, December 4, 2025, at 11:00am ET (5:00pm CET)
Meetings with Management can be requested via direct contact with Medincell or via banking representatives.
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.
These treatments combine active pharmaceutical ingredients with our proprietary BEPO® technology, which enables controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable deposit.
Risperidone LAl was the first treatment based on BEPO® technology to be approved by the FDA – first for schizophrenia in April 2023, and later for Bipolar | Disorder in October 2025. It is marketed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeqâ„¢). Medincell’s risperidone LAl was also approved for schizophrenia in Canada and South Korea in 2025.
Our investigational pipeline includes numerous innovative therapeutic candidates in various stages of development, from formulation to Phase 3 clinical trials. We collaborate with leading pharmaceutical companies and foundations to advance global health through new treatment options.
Headquartered in Montpellier, France, Medincell employs over 140 people representing more than 25 nationalities.
medincell.com
UZEDY® and SteadyTeq™ are trademarks of Teva Pharmaceuticals.
This press release may contain forward-looking statements, particularly concerning the progress of the Company’s clinical trials. Although the Company considers that its forecasts are based on reasonable assumptions, any statements other than statements of historical fact that may be contained in this press release relating to future events are subject to change without notice, to factors beyond the Company’s control and to the Company’s financial capabilities.
These statements may include, but are not limited to, any statements beginning with, followed by or including words or expressions such as
Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference
